DNC Biotechnology (CEO Park Sung-soo), a next-generation urine diagnostic solution and home healthcare specialist, announced on the 26th that it was finally selected for the biohealth medical device and digital healthcare sectors of the '2025 Ultra-Gap Startup Promotion Project (DIPS 1000+)' hosted by the Ministry of SMEs and Startups.
DNC Biotechnology, which was selected for the 'Super Gap Startup 1000+ Project', will receive direct support of up to 600 million won in commercialization funds over the next 3 years and up to 500 million won in R&D funds over 2 years after evaluation based on corporate demand, for a total of 1.1 billion won per company. In addition, it will receive linked support in the form of policy funds, guarantees, and exports.
In addition, through the designated leading organizations for each field, we plan to provide close support for the entire process required for corporate growth, from product/service advancement to demand discovery and investment attraction.
The next-generation urine diagnostic solution for medical institutions and urine diagnostic-based home healthcare from DNC Biotechnology, which was selected for this year's 'Super Gap Startup 1000+ Project', will reduce the workload of medical institution personnel by increasing the convenience and stability of the diagnostic testing process, and strengthen the accessibility and connectivity with medical institutions for individual users.
In addition, it is an innovative solution that helps in realizing preventive healthcare management and chronic disease management based on lifelog data and basic diagnosis data. In particular, the core technology, optical biosensor technology, has proven the technology and expertise of the solution by obtaining the New Health Technology Certification (NET).
DNC Biotechnology CEO Park Sung-soo said, “Through this selection for the Super Gap Startup 1000+ project, we have been recognized for the technological prowess, innovation, and business viability of the next-generation urine diagnostic solution we have developed.” He added, “We will become a global biohealth medical device company that contributes to the advancement of global public health by advancing our services through continuous R&D and technological innovation and enhancing our competitiveness in the global market.”
- See more related articles
You must be logged in to post a comment.